Compare Repligen Corporation Common Stock (RGEN) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs SAP SE — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while SAP SE trades at $218.51 (market cap $254.11B). The key difference: SAP SE is far larger — about 22.8× Repligen Corporation Common Stock's market cap, and SAP SE pays a 1.33% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and SAP SE for 118 Days on average.
| RGEN | SAP | |
|---|---|---|
Market Cap | $11.14B | $254.11B |
Volume | 1,259,263 | 2,139,071 |
Sector | Health | Technology |
52-Week High | $194.57 | $280.46 |
52-Week Low | $102.87 | $146.38 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $11.02B | $252.86B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SAP trades at $220.49, up 1.21% today, with a bullish technical outlook supported by moving averages and a consensus price target of $253.60. The company reported strong revenue growth to $36.80B in 2025 and a net income margin of 20.41%, though Q2 2026 EPS missed expectations. Recent news highlights AI-driven cloud revenue growth and partnerships, while cash flow trends show variability with a net outflow of $1.39B in 2025.
The stock presents upside potential based on analyst targets and robust fundamentals, but risks include competitive pressures in enterprise software and execution challenges in AI integration. Investors should weigh solid profitability against valuation multiples like a P/E of 29.48, which may limit near-term gains if growth moderates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
